... have tried and failed to develop an HIV vaccine, ...red "super antibodies" to fend off the virus befo...odies have proved impossible to produce in people....by Nature , scientists at The Rockefeller Univers...fied a diverse team of antibodies in "slow-progre...
...ute of Environmental Health Sciences (NIEHS), part...have a major presence at the annual Society of Tox... from the NIEHS and the National Toxicology Progra... grantees and collaborators, will share the newest...of toxicology. , Why: The SOT Annual Meeting is t...
...g technologies are giving marine conservationists ... climate change, that are contributing to declinin...ntil recently, scientists provided fishery manager... estimates, said Charles Greene, Cornell professor...blished in the March issue (Vol. 22, No. 1) of the...
Other Biology News:A natural approach for HIV vaccine 2A natural approach for HIV vaccine 3Hear about emerging trends in toxicology research 2New tracking tags are providing fish-eye views of ways to manage depressed fisheries 2(Date:11/19/2009)... NEW YORK, Nov. 19 NeoSt...it has sent the following letter to its shareholde...er 30, 2009, of China Biopharmaceuticals Holdings,...pany based in the People,s Republic of China. The ... Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prima...
(Date:11/19/2009)..., MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRN...Decision Resources find that the leading driver of...urope is broad-spectrum activity against gram-posi...ty of organisms that can cause nosocomial pneumoni...ook primarily for agents that provide appropriate ...
(Date:11/19/2009)... MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeut...atient in a randomized Phase 2B study of AEG35156,...elopment for multiple oncology indications. ,, ...e 2 Study of the X-Linked Inhibitor of Apoptosis (... High-dose Cytarabine and Idarubicin in AML Follow...
(Date:11/19/2009)... World,s Top Gene Synthesis Compani...GSC) to Coordinate Best Practices in Risk Reductio... Worldwide Gene Synthesis Capacity , ...he world’s leading gene synthesis companies ...ommon screening protocol to promote biosecurity in...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4...e Patient,Advocate Foundation (PAF), with support ...unce the launch of the Lymphedema CareLine (LCL). ... national, toll-free patient/provider,hotline desi...st cancer,patients who are or may be at risk for p...lling due to blockage in the lymphatic system). , ...
...oSciences has turned to MBI International to join ...lity of an important bio-based product line. MBI I...en research and commercialization through collabor...quo;s unique “Collaborative De-Risking&rdquo...ncertainties, which impede new technologies from g...
...ingpank, MD, FACS, as Principal Investigator , ...aq: DCTH ) announced today that the Hillman Can...al Center (UPMC), has joined Delcath,s Phase III c...fusion (PHP) System against inoperable metastatic ...Associate Professor Surgery in the Department of S...
Other Biology Technology:New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 3 DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 2Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 3Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 4Human Apo(a) ELISA Kit from Mercodia AB
Monkey sICAM-1 ELISA Kit from Bender MedSystems
BioBank -80nullC Automated sample library management system with CO2 backup from Thermo Scientific
...e) EIA Principle: The Oxidized LDL Competitive E...ized LDL in the sample competes with a fixed amoun... the binding of the biotin- labeled specific antib...Oxidized LDL Competitive Enzyme-Linked Immunosorbe...
Biology Products: